Trodelvy Better Than Chemo at Prolonging Survival in Advanced TNBC, Trial Shows

Trodelvy Better Than Chemo at Prolonging Survival in Advanced TNBC, Trial Shows
Immunomedics has announced that its Phase 3 ASCENT trial of Trodelvy (sacituzumab govitecan) met its main goal of demonstrating that the medication is superior to standard chemotherapy at delaying disease progression and prolonging the survival of people with metastatic triple-negative breast cancer (mTNBC). The biopharmaceutical company had closed ASCENT (NCT02574455) early, in April, due to the strong evidence already gathered of Trodelvy’s ability to halt disease progression in these patients. “The results of the global Phase 3 ASCENT study confirm our initial observations that sacituzumab govitecan has the potential to change the standard management of mTNBC,” Aditya Bardia, MD, MPH, principal investigator of ASCENT, said in a press release. Bardia also is director of precision medicine at the Center for Breast Cancer at the Massachusetts General Hospital Cancer Center and an assistant professor of medicine at Harvard Medical School, “Based on these data, sacituzumab govitecan has set a new benchmark in scientific and clinical innovation for patients with mTNBC by offering a novel alternative to the common drugs currently in clinical practice,” Bardia said. Trodelvy is a targeting agent called an antibody-drug conjugate, which is made up of an antibody targeting TROP-2 — a protein found in different types of tumors, including more than 90% of those in TNBC patients — that is linked to a toxic compound. Once the antibody binds to cancer cells that produce the TROP-2 protein, the toxic compound is released, eliminating them. The U.S. Food and Drug Administration recently approved Trodelvy, under its accelerated approval program, as a third-line treatment for people with mTNBC. That approval was based on data from 108 TNBC pati
Subscribe or to access all post and page content.